Dose Intensification of Daunorubicin and Cytarabine During Treatment of Adult Acute Lymphoblastic Leukemia: Results of Cancer and Leukemia Group B Study 19802

Cancer and Leukemia Group B (CALGB) Study 19802, a phase 2 study, evaluated whether dose intensification of daunorubicin and cytarabine could improve disease-free survival (DFS) in adults with acute lymphoblastic leukemia (ALL) and whether high-dose systemic and intrathecal methotrexate could replac...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2013-01, Vol.119 (1), p.90-98
Main Authors: STOCK, Wendy, JOHNSON, Jeffrey L, MCDONNELL, Diane, MROZEK, Krzysztof, BLOOMFIELD, Clara D, LARSON, Richard A, STONE, Richard M, KOLITZ, Jonathan E, POWELL, Bayard L, WETZLER, Meir, WESTERVELT, Peter, MARCUCCI, Guido, DEANGELO, Daniel J, VARDIMAN, James W
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Central Nervous System Neoplasms - prevention & control
Combined Modality Therapy
Cytarabine - administration & dosage
Daunorubicin - administration & dosage
Disease-Free Survival
Female
Hematologic and hematopoietic diseases
Humans
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Methotrexate - administration & dosage
Middle Aged
Neoplasm Metastasis - prevention & control
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality
Precursor Cell Lymphoblastic Leukemia-Lymphoma - radiotherapy
Remission Induction
Survival Rate
Tumors
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer and Leukemia Group B (CALGB) Study 19802, a phase 2 study, evaluated whether dose intensification of daunorubicin and cytarabine could improve disease-free survival (DFS) in adults with acute lymphoblastic leukemia (ALL) and whether high-dose systemic and intrathecal methotrexate could replace cranial radiotherapy for central nervous system (CNS) prophylaxis. One hundred sixty-one eligible, previously untreated patients ages 16 to 82 years (median age, 40 years) were enrolled, and 33 (20%) were aged ≥60 years. One hundred twenty-eight patients (80%) achieved complete remission (CR). Dose intensification of daunorubicin and cytarabine was feasible. At a median follow-up of 10.4 years for surviving patients, the 5-year DFS rate was 25% (95% confidence interval, 18%-33%), and the overall survival (OS) rate was 30% (95% confidence interval, 23%-37%). Patients aged
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.27617